Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large trial against multiple variants across three continents.

J&J's COVID-19 vaccine 66% effective in large global trial

The company plans to file for emergency use authorization in the US in early February.

Johnson & Johnson single-dose COVID vaccine is 66% effective, company says

In the U.S. the vaccine had an effectiveness of 72% but that number dropped to just 57% in South Africa where a more infectious variant of the virus is spreading.

Johnson & Johnson's Single-Dose Covid-19 Vaccine Is 66% Effective In Global Trial, But Has Lower Efficacy Against South African Variant

Johnson & Johnson said Friday a Phase 3 trial of its one-dose COVID-19 vaccine proved to be 66% effective overall in preventing moderate-to-severe disease 28 days after vaccination, raising hopes it may receive emergency use authorization in the U.S. in the coming weeks. The vaccine candidate was 72% effective in the U.S. trial, the company said in a statement.

Johnson & Johnson says COVID vaccine was 66% effective in Phase 3 trial

The US effort to halt the coronavirus got some good news on Friday as another vaccine succeeded in the final stages of clinical research. The single-dose vaccine, developed by healthcare giant Johnson & Johnson with US government funding, proved to be 66% effective at preventing people from catching COVID-19, J&J said in a statement. That's significantly lower than the protection offered by shots from Pfizer and from Moderna, though both of those shots require two doses.

J&J's single-dose coronavirus vaccine is 66% effective against COVID-19, raising worries that some variants may lower protection

The Covid vaccine was well tolerated, with no significant safety concerns related to the vaccine reported, J&J said. There were also no reports of anaphylaxis.

J&J says its one-shot Covid vaccine is 72% effective in the U.S., but less potent in other regions

NEW BRUNSWICK, N.J., Jan. 29, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen...

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Pfizer

Pfizer already is putting its COVID-19 vaccine into people's arms, while Johnson & Johnson's is waiting to be approved.

Better Coronavirus Stock: Johnson & Johnson vs. Pfizer

A single-shot vaccine developed by the healthcare giant Johnson & Johnson is up to 85% effective in preventing the most serious coronavirus symptoms, according to data from mass trials.

Single-shot COVID vaccine from Johnson & Johnson up to 85% effective

Johnson & Johnson will start COVID-19 vaccine supply with 2 million doses on receiving an emergency use authorization in the U.S., according to Government Accountability Office (GAO) report.

Johnson & Johnson To Start With 2 Million Doses COVID-19 Vaccine Supply

Stay tuned for phase 3 results in the coming days.

This Company May Be the Next to Cross the Coronavirus Vaccine Finish Line

Boeing

JPMorgan Chase & Co

Microsoft

A Positive and Reassuring Earnings Picture

The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high.

JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus

I believe Johnson & Johnson is overvalued, and offer a demonstration. I also believe that it is overvalued enough to warrant selling part of the position.

Breaking Up With Johnson & Johnson: It's Not You, It's Me

Hello, Walgreens is officially getting a new leader — Starbucks COO Roz Brewer has been named the retail pharmacy's next CEO. That'll make her the only Black woman leading a Fortune 500 company.

J&J vaccine data is imminent

Johnson & Johnson expects to "soon" unveil the results of its coronavirus vaccine in Phase 3 testing, the company said in a report — leading JNJ stock to pop. So, is JNJ stock a buy?

Is JNJ Stock A Buy On Plans To 'Soon' Unveil Covid Vaccine Test Results?

The company promises that news about its vaccine is coming soon.

Johnson & Johnson Rises on Q4 Beats, Coronavirus Vaccine Hopes

Shares of Johnson & Johnson (NYSE:JNJ), a major drug manufacturer, climbed approximately 3% on Tuesday on the back of reporting fourth-quarter earnings results that topped analyst estimates.

Johnson & Johnson Rises on 4th-Quarter Earnings Beat

Johnson & Johnson reported on Tuesday (Jan. 26) as part of its financial results that reported sales grew by 8.3 percent from Q4 2019 to Q4 2020, as consumer health and pharmaceutical sales rose while medical devices worldwide operational sales fell amid the pandemic. The company reported that consumer health worldwide operational sales grew 3.1 […]

Johnson & Johnson Sales Rise 8.3 Pct Amid Consumer Health, Pharmaceutical Growth

Johnson & Johnson (JNJ) CEO Alex Gorsky on Q4 2020 Results - Earnings Call Transcript

Johnson & Johnson expects to share details from the Phase 3 clinical trial for its COVID-19 vaccine candidate "early next week," according to remarks made by CEO Alex Gorsky on Tuesday during an earnings call. J&J's stock was up 3.0% in trading on Tuesday afternoon.

J&J CEO: Expect Phase 3 results for its COVID-19 vaccine candidate early next week

The world is days away from getting crucial results on one of the most important coronavirus vaccines in development. Johnson & Johnson CEO Alex Gorsky said Tuesday the healthcare giant will have results from a 45,000-person study testing its single-dose COVID-19 vaccine by early next week.

Johnson & Johnson's CEO says crucial coronavirus vaccine data will come by early next week

The healthcare giant beat Wall Street expectations in Q4 and gave encouraging guidance for 2021.

Here's Why Investors Cheered Johnson & Johnson's Q4 Results

Johnson & Johnson (NYSE:JNJ) released its fourth-quarter fiscal 2020 results before the opening bell on Jan. 26. The world's biggest maker of consumer health care products posted an earnings and revenue beat and provided a strong outlook for the full-year 2021.

Johnson & Johnson Shares Pop on Stronger-Than-Expected 4th-Quarter Results

J&J (JNJ) beats fourth-quarter 2020 estimates for both earnings and sales. It issues its adjusted earnings and sales outlook for 2021.

News for Johnson & Johnson Stock (JNJ)